PHARMACEUTICAL COMPOSITIONS COMPRISING DASATINIB ANHYDROUS AND USES THEREOF

Pharmaceutical compositions comprising dasatinib anhydrous provide an improved, pH-independent dissolution profile compared with pharmaceutical compositions comprising dasatinib monohydrate. Thus, pharmaceutical compositions comprising dasatinib anhydrous can be used in the treatment of chronic myel...

Full description

Saved in:
Bibliographic Details
Main Authors HOFMANN, Jiri, BARTUNEK, Ales, NOVAK, Martin, SEDMAK, Gregor
Format Patent
LanguageEnglish
French
German
Published 11.01.2023
Subjects
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

Abstract Pharmaceutical compositions comprising dasatinib anhydrous provide an improved, pH-independent dissolution profile compared with pharmaceutical compositions comprising dasatinib monohydrate. Thus, pharmaceutical compositions comprising dasatinib anhydrous can be used in the treatment of chronic myelogenous leukaemia (CML) and/or Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL), especially in subjects having an increased gastric pH and/or in subjects being co-administered with a gastric acid reducing agent.
AbstractList Pharmaceutical compositions comprising dasatinib anhydrous provide an improved, pH-independent dissolution profile compared with pharmaceutical compositions comprising dasatinib monohydrate. Thus, pharmaceutical compositions comprising dasatinib anhydrous can be used in the treatment of chronic myelogenous leukaemia (CML) and/or Philadelphia chromosome positive (Ph+) acute lymphoblastic leukaemia (ALL), especially in subjects having an increased gastric pH and/or in subjects being co-administered with a gastric acid reducing agent.
Author BARTUNEK, Ales
HOFMANN, Jiri
SEDMAK, Gregor
NOVAK, Martin
Author_xml – fullname: HOFMANN, Jiri
– fullname: BARTUNEK, Ales
– fullname: NOVAK, Martin
– fullname: SEDMAK, Gregor
BookMark eNrjYmDJy89L5WTwDvBwDPJ1dHYNDfF0dvRRcPb3DfAP9gzx9PcLBnOCPIM9_dwVXByDHUM8_TydFBz9PCJdgvxDg4EsF4XQYNdghRAP1yBXfzceBta0xJziVF4ozc2g4OYa4uyhm1qQH59aXJCYnJqXWhLvGmBiaGhibGbmaGhMhBIAmQgvew
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate COMPOSITIONS PHARMACEUTIQUES COMPRENANT DU DASATINIB ANHYDRE ET LEURS UTILISATIONS
PHARMAZEUTISCHE ZUSAMMENSETZUNGEN MIT WASSERFREIEM DASATINIB UND VERWENDUNGEN DAVON
ExternalDocumentID EP4114366A1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP4114366A13
IEDL.DBID EVB
IngestDate Fri Jul 19 14:51:53 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP4114366A13
Notes Application Number: EP20210710460
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230111&DB=EPODOC&CC=EP&NR=4114366A1
ParticipantIDs epo_espacenet_EP4114366A1
PublicationCentury 2000
PublicationDate 20230111
PublicationDateYYYYMMDD 2023-01-11
PublicationDate_xml – month: 01
  year: 2023
  text: 20230111
  day: 11
PublicationDecade 2020
PublicationYear 2023
RelatedCompanies Zentiva K.S
RelatedCompanies_xml – name: Zentiva K.S
Score 3.4419856
Snippet Pharmaceutical compositions comprising dasatinib anhydrous provide an improved, pH-independent dissolution profile compared with pharmaceutical compositions...
SourceID epo
SourceType Open Access Repository
SubjectTerms HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Title PHARMACEUTICAL COMPOSITIONS COMPRISING DASATINIB ANHYDROUS AND USES THEREOF
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20230111&DB=EPODOC&locale=&CC=EP&NR=4114366A1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDI6mgYAbDBDjpRxQbxWs7dpxmFCXpLSgPtQHGqdpaVNpl25iRfx9nGgbXODmJJIVWbH92YkdhO4qbjzwaljr4I1K3XIcR5_b3NRrYdh1aRuiFDKhH0a2X1gv0-G0gxbbWhjVJ_RLNUcEjSpB31tlr1c_SSyq3lau7_kCppZPXj6m2iY6NuRxHWh0MmZJTGOiEQKUFqVjC3C_adsuBEp7gKIdqQzsbSKLUla_PYp3jPYTYNa0J6gjmh46JNuP13roINzcdwO5Ub31KXpNfDcNXcKKXLYwwCQOkzgLVBWwGqRBFkTPmLqZmwdRMMFu5L_TNC4yoCguwHDi3Gcpi70zhD2WE1-HXc12EpixZLd_8xx1m2UjLhDm5ciswOVyiDosUdejxxoA3KiCmGTOAdb0Uf9PNpf_rF2hIylKmWgYDK5Rt_34FDfgelt-q4T2DZotgm4
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8MwDLamgRg3GCDGMwfUWwVru3YcJtQ1LS1bH-oDjdO0tKm0SzexIv4-TjUGF7g5iWRFVmx_dmIH4K5gygMrBqWM3iiXNcMw5IXOVLnkil7musJzLhL6fqC7mfYyG8xasPyuhWn6hH42zRFRo3LU97qx1-ufJBZt3lZu7tkSp1ZPTjqi0jY6VsRx7Ut0PLKjkIaWZFlISUE80hD3q7puYqC0hwjbEMpgv45FUcr6t0dxjmA_QmZVfQwtXnWhY31_vNaFA397343kVvU2JzCJXDP2TcvOUtHCgFihH4WJ11QBN4PYS7zgmVAzMVMv8MbEDNw3GodZghQlGRpOkrp2bIfOKRDHTi1Xxl3NdxKY29Fu_-oZtKtVxc-BsHyoFuhyGUYdGi_L4WOJAG5YYEyyYAhretD7k83FP2u30HFTfzqfesHkEg6FWEXSod-_gnb9_sGv0Q3X7KYR4BfkYoVh
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=PHARMACEUTICAL+COMPOSITIONS+COMPRISING+DASATINIB+ANHYDROUS+AND+USES+THEREOF&rft.inventor=HOFMANN%2C+Jiri&rft.inventor=BARTUNEK%2C+Ales&rft.inventor=NOVAK%2C+Martin&rft.inventor=SEDMAK%2C+Gregor&rft.date=2023-01-11&rft.externalDBID=A1&rft.externalDocID=EP4114366A1